זקטרן וטרינרי
beit-erez havat milatin ltd - gamithromycin - תמיסה להזרקה - gamithromycin 150 mg/ml
טיקוואק 0.5 מל
pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus
טיקוואק ג'וניור 0.25 מל
pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 1.2 mcg / 0.25 ml - encephalitis, tick borne, inactivated, whole virus
נורומקטין זריקה וטרינרי
comex ltd - ivermectin - תמיסה להזרקה - ivermectin 10 mg/ml
נורפניקול 300 מגמל זריקה וטרינרי
comex ltd., israel - florfenicol - תמיסה להזרקה - florfenicol 300 mg/ml
פינדין וטרינרי
intervet ( israel) ltd - flunixin as meglumine - תמיסה להזרקה - flunixin as meglumine 50 mg/ml
קימריה
novartis israel ltd - tisagenlecleucel - tisagenlecleucel
בינוקריט 1000 יחבל 0.5 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
בינוקריט 2000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
בינוקריט 30000 יחבל 0.75 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob